Menopausal hormone therapy and risk of liver cancer in a swedish population-based cohort study - PubMed
5 hours ago
- #Liver Cancer
- #Menopausal Hormone Therapy
- #Hepatocellular Carcinoma
- Menopausal hormone therapy (MHT) may decrease the risk of hepatocellular carcinoma (HCC).
- The study found a hazard ratio (HR) of 0.45 for HCC among MHT users.
- Both estrogen-only (HR 0.42) and estrogen-progestogen combinations (HR 0.49) showed reduced HCC risk.
- Risk reduction was more pronounced in women aged 60 or older (HR 0.37).
- MHT was not associated with a reduced risk of intrahepatic cholangiocarcinoma (HR 0.99).
- The study adjusted for factors like smoking, alcohol-related diagnoses, diabetes, and obesity.